Fennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record High

Fennec's Pedmark is reportedly the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients. Fennec Pharmaceuticals reported its strongest quarter yet for Pedmark (sodium thiosulfate injection), with second-quarter 2026 net product sales climbing to $17.1 million, up 78% year over year compared to $9.7 million in the same period a year earlier. The Research Triangle Park, NC-based specialty pharmaceutical company also posted a non-GAAP adjusted EBITDA of $2.8 million for the quarter, versus an adjusted EBITDA loss of $1.2 million in Q2 2025 — marking what the company calls a record quarter for that metric. The results represent the company's seventh consecutive quarter of growth and come as Fennec continues to expand its sales organization and broaden Pedmark's reach across both established and new accounts, including in the adolescent and young adult (AYA) population.